These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 18450609)

  • 1. Sirolimus for lymphangioleiomyomatosis lesions.
    Egan JJ; Remund KF; Corris P
    N Engl J Med; 2008 May; 358(18):1963-4; author reply 1964. PubMed ID: 18450609
    [No Abstract]   [Full Text] [Related]  

  • 2. Summaries for patients. Sirolimus therapy in patients with lymphangioleiomyomatosis.
    Ann Intern Med; 2011 Jun; 154(12):I44. PubMed ID: 21690578
    [No Abstract]   [Full Text] [Related]  

  • 3. Sirolimus treatment for recurrent lymphangioleiomyomatosis after lung transplantation.
    Chen F; Omasa M; Kondo N; Fujinaga T; Shoji T; Sakai H; Bando T
    Ann Thorac Surg; 2009 Jan; 87(1):e6-7. PubMed ID: 19101258
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Resolution of Thoracic and Abdominal Lymphangioleiomyomas in a Patient With Lymphangioleiomyomatosis Treated With Sirolimus.
    Cabeza Osorio L; Ruiz Cobos MÁ; Casanova Espinosa Á
    Arch Bronconeumol; 2016 Jun; 52(6):329-30. PubMed ID: 25912780
    [No Abstract]   [Full Text] [Related]  

  • 5. Mayo clinic experience of lung transplantation in pulmonary lymphangioleiomyomatosis.
    Ussavarungsi K; Hu X; Scott JP; Erasmus DB; Mallea JM; Alvarez F; Lee AS; Keller CA; Ryu JH; Burger CD
    Respir Med; 2015 Oct; 109(10):1354-9. PubMed ID: 26321137
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Novel Quantitative Computed Tomographic Analysis Suggests How Sirolimus Stabilizes Progressive Air Trapping in Lymphangioleiomyomatosis.
    Argula RG; Kokosi M; Lo P; Kim HJ; Ravenel JG; Meyer C; Goldin J; Lee HS; Strange C; McCormack FX;
    Ann Am Thorac Soc; 2016 Mar; 13(3):342-9. PubMed ID: 26799509
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Changes in lung function and chylous effusions in patients with lymphangioleiomyomatosis treated with sirolimus.
    Taveira-DaSilva AM; Hathaway O; Stylianou M; Moss J
    Ann Intern Med; 2011 Jun; 154(12):797-805, W-292-3. PubMed ID: 21690594
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of sirolimus in the treatment of lymphangioleiomyomatosis: favorable responses in patients with different extrapulmonary manifestations.
    Freitas CS; Baldi BG; Araújo MS; Heiden GI; Kairalla RA; Carvalho CR
    J Bras Pneumol; 2015; 41(3):275-80. PubMed ID: 26176526
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Durability of Sirolimus for Lymphangioleiomyomatosis.
    Martirossian A; Shah S; Carrete L; Valle J; Valentine V
    Am J Med Sci; 2017 Dec; 354(6):603-607. PubMed ID: 29208258
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sirolimus amelioration of clinical symptoms of recurrent lymphangioleiomyomatosis after living-donor lobar lung transplantation.
    Sugimoto R; Nakao A; Yamane M; Toyooka S; Okazaki M; Aoe M; Seyama K; Date H; Oto T; Sano Y
    J Heart Lung Transplant; 2008 Aug; 27(8):921-4. PubMed ID: 18656809
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lymphangioleiomyomatosis treatment with sirolimus.
    Casanova A; María Girón R; Acosta O; Barrón M; Valenzuela C; Ancochea J
    Arch Bronconeumol; 2011 Sep; 47(9):470-2. PubMed ID: 21440356
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic Effect of Sirolimus for Lymphangioleiomyomatosis Remaining in the Abdominopelvic Region After Lung Transplantation: A Case Report.
    Ito T; Suno M; Sakamoto K; Yoshizaki Y; Yamamoto K; Nakanishi R; Hirano Y; Irie M; Kurosaki T; Otani S; Yamane M; Sugimoto S; Miyoshi K; Oto T
    Transplant Proc; 2016; 48(1):271-4. PubMed ID: 26915883
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lymphangioleiomyomatosis.
    Sclafani A; VanderLaan P
    N Engl J Med; 2018 Jun; 378(23):2224. PubMed ID: 29874537
    [No Abstract]   [Full Text] [Related]  

  • 14. Regression of pulmonary lymphangioleiomyomatosis (PLAM)-associated retroperitoneal angiomyolipoma post-lung transplantation with rapamycin treatment.
    Krishnan A; Sandrini A; Yates D
    J Heart Lung Transplant; 2008 Nov; 27(11):1268. PubMed ID: 18971103
    [No Abstract]   [Full Text] [Related]  

  • 15. Highly effective sirolimus therapy for abdominal lymphangioleiomyoma.
    Lecuelle D; Basille D; Renard C; Saint F; Jounieaux V
    Respir Med Res; 2019 May; 75():32-34. PubMed ID: 31262426
    [No Abstract]   [Full Text] [Related]  

  • 16. Sustained effects of sirolimus on lung function and cystic lung lesions in lymphangioleiomyomatosis.
    Yao J; Taveira-DaSilva AM; Jones AM; Julien-Williams P; Stylianou M; Moss J
    Am J Respir Crit Care Med; 2014 Dec; 190(11):1273-82. PubMed ID: 25329516
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of Treatment response to Sirolimus in pulmonary lymphangioleiomyomatosis by longitudinal quantification of cystic changes using automated post-processing of chest CT-data.
    Albtoush OM; Horger M
    Rofo; 2020 Dec; 192(12):1202-1204. PubMed ID: 32408352
    [No Abstract]   [Full Text] [Related]  

  • 18. Should mammalian target of rapamycin inhibitors be stopped in women with lymphangioleiomyomatosis awaiting lung transplantation?
    El-Chemaly S; Goldberg HJ; Glanville AR
    Expert Rev Respir Med; 2014 Dec; 8(6):657-60. PubMed ID: 25199529
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Consensus Statement: sirolimus (rapamycin) as therapy for lymphangioleiomyomatosis (2018)].
    ; ; ;
    Zhonghua Jie He He Hu Xi Za Zhi; 2019 Feb; 42(2):92-97. PubMed ID: 30704178
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lymphangioleiomyomatosis: a rare indication for lung transplantation.
    Shitrit D; Izbicki G; Ben-Dov I; Kramer MR
    Isr Med Assoc J; 2003 Jul; 5(7):533. PubMed ID: 12901257
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.